SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals cuts price of antiviral drug Favipiravir

14 Jul 2020 Evaluate

Glenmark Pharmaceuticals has cut price of antiviral drug Favipiravir --sold under the brand name FabiFlu for the treatment of patients with mild to moderate COVID-19 by 27 percent to Rs 75 per tablet. The company had launched the drug in June at a price of Rs 103 per tablet.

The price reduction has been made possible through benefits gained from higher yields and better scale, as both the active pharmaceutical ingredient (API) and formulations are made at Glenmark's facilities in India, the benefits of which are being passed on to patients in the country.

Glenmark Pharmaceuticals is a global researchled pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

2244.90 -3.00 (-0.13%)
20-Apr-2026 09:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1677.45
Dr. Reddys Lab 1234.80
Cipla 1241.25
Zydus Lifesciences 948.10
Lupin 2332.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×